Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

Study investigates COVID-19 vaccination in pregnancy

A new study discusses the risk of COVID-19-related complications in pregnancy and the role of vaccination in reducing this risk.

17 May 2022

Mice live longer with nasal gene therapy

In a recent study published in the Proceedings of the National Academy of Sciences journal, researchers assessed the efficiency of a novel intranasal and injectable therapy in improving life expectancy.

17 May 2022

Review portrays clinical journey of messenger RNA vaccines and mRNA-based therapies

Researchers reviewed messenger ribonucleic acid (mRNA) technology and highlighted its clinical applications.

11 May 2022

Bacteria-mediated oral delivery of viral replicon-based mRNA vaccines

Scientists have discussed the possibilities of developing oral replicon-based mRNA vaccines against SARS-CoV-2.

4 May 2022

How protection due to vaccination or previous SARS-CoV-2 infection varies for the population of the Czech Republic

The current study aimed to understand how far this reduced vaccine efficacy and the protection conferred by prior infection in terms of Omicron infection, hospitalization, and oxygen supplementation.

4 May 2022

$Can fractional doses of COVID-19 vaccines protect against SARS-CoV-2?$

Can fractional doses of COVID-19 vaccines protect against SARS-CoV-2?

A recent research paper posted to the Research Square* preprint server assessed the dose fractionation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.

1 May 2022

Comparative analysis of transcriptional responses across 13 different vaccines

A new study aimed to carry out a comparative analysis of transcriptional responses from 820 healthy young adults across 13 different vaccines.

27 Apr 2022

Antibodies against the original strain of SARS-CoV-2 may not work as well with omicron

If you're wondering why after two vaccination doses and a booster shot, you still got sick from the omicron strain of the virus that causes COVID-19, one possible answer may have been found in a recent study by researchers at Johns Hopkins Medicine and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

26 Apr 2022

Vaccine effectiveness against symptomatic disease caused by the Omicron and Delta variants in England

The researchers aimed to estimate how effective vaccination was against severe COVID-19, caused by Omicron and Delta variants of the virus, in England.

25 Apr 2022

Study: A considerable number of healthcare workers took sick leave after COVID-19 vaccination

A third of healthcare workers took sick leave after being vaccinated against COVID-19, a German study presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal, (23-26 April) has found.

23 Apr 2022

Hybrid alphavirus-SARS-CoV-2 pseudovirus system rapidly measures neutralizing antibodies

Do a person's antibodies work to block the COVID-19 virus from infecting one's system? Are these antibodies also capable of blocking emerging variants such as the omicrons?

21 Apr 2022

Does COVID-19 vaccination benefit those with prior SARS-CoV-2 infection?

Researchers evaluate the effectiveness of four COVID-19 vaccines against symptomatic infection, hospitalization, and death in convalescent individuals.

5 Apr 2022

Preclinical investigation of intranasal adjuvanted COVID-19 vaccine

A new study reported systemic and mucosal immunity against SARS-CoV-2 via intranasal delivery of a vaccine containing recombinant SARS-CoV-2 antigens, nucleocapsid, and spike subunit.

30 Mar 2022

Study evaluates humoral and cellular immune memory induced by different COVID-19 vaccines

Researchers evaluated the humoral and cellular immune memory induced by four COVID-19 vaccines representing three different vaccine platforms.

24 Mar 2022

New approach could lead to quicker generation of effective, personalized cancer vaccines

Scientists have created a pipeline for identifying, prioritizing and evaluating potential tumor antigens for the fast generation of cancer vaccines, according to a report published today in eLife.

22 Mar 2022

Study shows BCG vaccination reduces SARS-CoV-2-induced lung inflammation in hamsters

Researchers tested the effectiveness of the BCG vaccine in SARS-CoV-2-infected Syrian hamsters.

18 Mar 2022

Synthetic viral vector and surgical approach enable efficient gene transfer into the inner ear of primates

A synthetic viral vector and a novel surgical approach developed at Mass Eye and Ear has enabled efficient gene transfer into the inner ear of nonhuman primates, a research team working towards the development of effective treatments for hearing loss and vestibular disorders has reported.

15 Mar 2022

Three new drug companies join the COVIDRIVE consortium to study vaccine effectiveness

Three new drug companies (Moderna, Novavax and Valneva) have joined the COVIDRIVE consortium, becoming partners of this project coordinated by the Vaccine Research Department of the Foundation for the Promotion of Health and Biomedical Research of Valencia Region (Fisabio), an affiliate of the Conselleria de Sanitat Universal i Salut Pública, along with the company specialized in pharmacovigilance and epidemiology, P95.

8 Mar 2022

Intersectional, anterograde transsynaptic targeting system used to reveal two different brain circuits

Osaka Metropolitan University uses new “intersectional, anterograde transsynaptic targeting system” to reveal two different mouse brain circuits: the retina/primary visual cortex to the superior colliculus and the bilateral motor cortex to the dorsal striatum.